Skip to content

Innovative, accessible treatments for the leading causes of death globally

At George Medicines, we believe single-pill, multi-mechanism combinations of existing medicines offer the potential to better manage non-communicable diseases and could have a positive social impact by improving lives and reducing the financial burden on patients and health systems.

About Us +

Welcome to
George Medicines

Multiple drugs are increasingly being prescribed to adequately control conditions such as hypertension, cardiovascular disease and type 2 diabetes. This can be complicated for patients and costly for health systems. At George Medicines we are using our drug development expertise and the latest formulation approaches to combine existing medicines into novel, single-pill therapies with the potential to bring significant improvements in clinical outcomes and adherence.

Our Approach +

About Us

George Medicines is a venture-backed, spin-out company from George Health, initially established to commercialise the research of The George Institute for Global Health, one of the world’s leading health research institutes. Learn more about the Institute in its latest Annual Report.

We use the research base and scientific expertise of The George Institute to pursue the late-stage development of our single-pill combination therapies.

 

MORE INFO +

Our Approach

Our differentiated business model avoids the early, high-risk stages of drug discovery and development by formulating established drugs into innovative, single-pill, multi-mechanism combinations using proprietary technology, which reduces time-to-market and brings a higher probability of success while requiring less capital investment than is usual in the industry.

MORE INFO +

Pipeline

We are building a strong and diversified proprietary pipeline of innovative, single-pill combination therapies, targeting some of the leading causes of death in both developed and developing countries, including hypertension, diabetes and other common cardiometabolic disorders.

MORE INFO +

Partners

Our strategy is to advance our late-stage pipeline through the final stages of development and to secure approval from global regulators. We work alongside appropriate partners to commercialise our therapies across the developed and developing world where our medicines can reduce the burden on health systems and have the biggest positive social impact.

MORE INFO +

News

29 June 2026

George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations

Brendan Walsh brings more than 20 years of operational leadership to support George Medicines’ global commercial expansion of GMRx2 London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today announces the appointment of Brendan Walsh as Senior Vice President of Supply …

READ MORE +
13 May 2026

In Conversation with Pamela Kushner, MD, Clinical Professor University of California at Irvine

In our latest Q&A series, and to mark Stroke Awareness Month, we spoke with Pamela Kushner, MD, Clinical Professor University of California at Irvine, about the evolving landscape of stroke prevention and care.   Over the past decade, how has our understanding of the role of measures to reduce the risk of stroke evolved? We …

READ MORE +
22 April 2026

New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

Significant lowering of systolic blood pressure of 9mmHg on top of background treatment maintained with GMRx2 over an average follow-up of 3 year Safety findings similar to previous studies of GMRx2 London, UK, Boston, MA, 22 April 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today …

READ MORE +
16 March 2026

George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement

Arrotex gains exclusive rights in Australia and New Zealand to innovative single pill combination of three hypertension medicines, including two doses that are lower than those currently available in single pill combinations GMRx2 is designed to deliver blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, with an established safety profile George …

READ MORE +

Publications

24 October 2024

Efficacy and safety of a novel low-dose triple single-pill combination, compared with dual combinations for treatment of hypertension

READ MORE +
31 August 2024

Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria

READ MORE +
31 August 2024

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension

READ MORE +
16 May 2024

Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke

READ MORE +

Part of a mission to deliver affordable and scalable treatments and technologies

George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world's leading medical research institutes with a focus on addressing global health inequity.

VIEW WEBSITE +